New patent grant for oligonucleotide modulators of blood coagulation factor aptamers

Sep 18 2009

Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that the European Patent Office (EPO) has notified the Company of its intent to grant a patent with claims directed to oligonucleotide modulators of blood coagulation factor aptamers in EP 1401853. This new patent grant in the Company's portfolio extends the scope and breadth of Regado's intellectual property estate.

"We are very pleased with the EPO's decision to grant claims from a patent we believe will be fundamental to the development of active control agents for therapeutic aptamers," said David J. Mazzo, Ph.D., President and Chief Executive Officer of Regado Biosciences, Inc. "This patent is key to the protection of the Company's lead product candidate, the REG1 anticoagulation system, and its grant enables the exclusive use of modulator technology in this field solely by Regado."

The allowed claims in EP1401853 broadly cover oligonucleotide modulators that hybridize under physiological conditions to a blood coagulation factor aptamer, and, in so doing, specifically and rapidly reverse the anticoagulant and antithrombotic effects of the aptamer. Upon completion of certain formalities, the patent should issue in approximately six months. Regado also controls certain U.S. patent applications and issued patents covering aspects of the REG1 system, including patents covering certain RNA aptamers to coagulation factors (e.g. US7,312,325) and aptamer modulation (e.g. US7,300,922) exclusively licensed from Duke University, as well as improved coagulation factor modulator systems (e.g., US7,304,041) owned by the Company.